[인터넷 바카라 사이트 USA] CELLinCELLS sees rising global interest in organoids… “Aiming for international technology export”

[by Ji, Yong Jun] “Global interest in 인터넷 바카라 사이트 USA has increased notably since the U.S. Food and Drug Administration (FDA) announced its plan in April to replace animal testing with organoid-based alternatives.”

CEO Cho Jae-jin of CELLinCELLS, in an interview with <THE 인터넷 바카라 사이트 at ‘인터넷 바카라 사이트 USA’ held in Boston on June 18 (local time), stated, “We have engaged in ongoing partnership discussions with approximately 40 인터넷 바카라 사이트technology companies, including pre-arranged business development (BD) meetings.” He added, “The primary objective of most meetings with major global pharmaceutical companies was technology scouting. There is a strong demand for new technologies related to organoids.”

Cho stated that global companies specializing in skin regeneration and facial aesthetics have shown particularly strong interest. “Our experience in conducting commercial clinical trials with organoids has established a credible track record,” he emphasized. “We are capable of applying these technologies to fundamental conditions for which no effective treatments currently exist, such as osteoarthritis and cartilage defect regeneration.”

CELLinCELLS completed Phase 1 clinical trials for ‘TRTP-101,’ an organoid-based skin regeneration treatment candidate for atrophic scars, in December 2024. The company successfully secured proof-of-concept (PoC) through top-line Phase 1 results, which demonstrated no dose-limiting toxicities or adverse drug reactions. These findings were presented at the Korean Society for Investigative Dermatology (KSID) in March. Additionally, CELLinCELLS has submitted a Phase 2 clinical trial plan (IND) application to the Ministry of Food and Drug Safety.

At the 인터넷 바카라 사이트 USA event, CELLinCELLS presented its proprietary ‘TRTP’ platform, a patented tissue morphology technology designed for standardization and mass production. This platform enables the generation of three-dimensional therapeutic organoids by spatially arranging patented stem cells used in organoid production in a mathematically structured framework.

Recently, interest in organoid technology has been increasing, largely due to its potential to serve as an alternative to animal models. In particular, the U.S. Food and Drug Administration (FDA) announced a roadmap in April outlining a phased transition away from traditional animal testing in the safety evaluation of ‘인터넷 바카라 사이트logics,’ such as monoclonal antibodies. The FDA aims to establish a system capable of proving safety through the use of artificial intelligence (AI)-driven computer modeling, organoid and organ-mimetic testing platforms, and human-derived data.

“The TRTP platform is applicable to a wide range of regenerative treatments, and we aim to leverage this versatility to drive technology exports,” Cho said.